{"id":"NCT01585584","sponsor":"University of Calgary","briefTitle":"Triple-Therapy in Patients With HCV Genotype 3 Who Previously Failed Treatment","officialTitle":"Triple-Therapy With PegInterferon α-2b + Ribavirin + Boceprevir in Patients With HCV Genotype 3 Who Previously Failed Treatment With PegInterferon α + Ribavirin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-05","primaryCompletion":"2014-12","completion":"2015-07","firstPosted":"2012-04-26","resultsPosted":"2015-09-21","lastUpdate":"2015-09-21"},"enrollment":11,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C"],"interventions":[{"type":"DRUG","name":"Boceprevir","otherNames":["VICTRELIS™","boceprevir capsules, 200 mg","Hepatitis C Virus (HCV) Protease Inhibitor"]}],"arms":[{"label":"Boceprevir","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to test the potential antiviral efficacy of triple-combination therapy with Peginterferon α-2b + ribavirin + boceprevir (PRB) in patients with HCV genotype 3 who previously failed Peginterferon α + ribavirin (non-responders or relapsers).","primaryOutcome":{"measure":"Sustained Virologic Response (SVR) at 24 Weeks Post Treatment","timeFrame":"24 weeks after treatment","effectByArm":[{"arm":"Victrelis Triple","deltaMin":6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":1,"countries":["Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":10},"commonTop":["Insomnia","Anemia","Local injection site reactions","Muscle pain","Chills"]}}